Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19

Br J Haematol. 2020 Aug;190(4):e189-e191. doi: 10.1111/bjh.16962. Epub 2020 Jul 19.

Andrew J Wilson^{1

2}, Ethan Troy-Barnes¹, Maryam Subhan¹, Fiona Clark¹, Rajeev Gupta^{1

3

2}, Adele K Fielding^{1

3}, Panagiotis Kottaridis¹, Marc R Mansour^{1

3}, Jenny O'Nions^{1

2}, Elspeth Payne^{1

3}, Naina Chavda², Robert Baker², Kirsty Thomson¹, Asim Khwaja^{1

3

2}

¹ Department of Haematology, University College London Hospital (UCLH), London, UK.
² UCLH Specialist Integrated Haematology Malignancy Diagnostic Service, Health Services Laboratories, London, UK.
³ Department of Haematology, University College London Cancer Institute, London, UK.

No abstract available

Publication types